Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Plan-les-Ouates, Geneva, Switzerland, focused on the discovery and development of novel orally available small molecule allosteric modulators for neurological disorders. The company's pipeline includes programs targeting mGlu5, mGlu2, mGlu7, and GABAB receptors for indications including post-stroke recovery, traumatic brain injury, substance use disorder, chronic cough, and anxiety-related disorders. Addex also launched a spin-out, Neurosterix, to advance M4 PAM allosteric modulators for schizophrenia. The company trades on SIX Swiss Exchange and has US ADRs listed.